What is the role of tepotinib (Tepmetko) in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Another oral MET inhibitor, tepotinib (Tepmetko) was recommended by the NCCN panel and also granted accelerated approval by the FDA for treatment of metastatic NSCLC in patients with MET exon 14 skipping mutation.

Efficacy was evaluated in the multicenter, open-label, single-arm, VISION trial enrolling 152 metastatic or advanced NSCLC patients with the METex14 skipping alterations received tepotinib until disease progression or unacceptable toxicity. The ORR was 43% in treatment naïve and previously treated patients. The median response duration for treatment naïve and previous treated patients was 10.8 months and 11.1 months. [206]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!